Corona Virus Disease 2019,COVID-19 Clinical Trial
Official title:
Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19
The study is expected to treat patients with mild and severe neo-coronary pneumonia through standard treatment regimens in combination with tetrandrine tablets, thereby reducing the clinical progress of some patients, improving prognosis, reducing the incidence of pulmonary fibrosis during rehabilitation, and improving patients' quality of life.
Since December 2019, a number of cases of pneumonia infected with the new coronavirus have
been found in wuhan, hubei province.Has now become a global epidemic of crisis.
After recent frontline anti-epidemic experience, the diagnostic and treatment specifications
for new coronary pneumonia have been updated several times. In the latest country,
"Specifications for the Diagnosis and Treatment of New Types of Coronary Pneumonia (Trial
Version 6)", the traditional Chinese medicines have again emphasized For the treatment of
patients, traditional Chinese medicine preparations such as Xuebijing and Qingfei Paidu
Decoction have been recommended, but the introduction of anti-fibrosis related drugs is still
lacking.Tetrandrine is a traditional Chinese medicine. Previous research has shown that it is
an antagonist of calmodulin, has anti-tumor, anti-inflammatory effects, and can effectively
inhibit fibroblasts, thereby inhibiting pulmonary fibrosis.The study is expected to treat
patients with mild and severe neo-coronary pneumonia through standard treatment regimens in
combination with tetrandrine tablets, thereby reducing the clinical progress of some
patients, improving prognosis, reducing the incidence of pulmonary fibrosis during
rehabilitation, and improving patients' quality of life.
;